Vaccine design efforts against the human immunodeficiency virus (HIV)have been greatly stimulated by the observation that many infected patients eventually develop highly potent broadly neutralizing antibodies (bnAbs).Importantly, these bnAbs have evolved to recognize not only the two protein components of the viral envelope protein (Env) but also the numerous glycans that form a protective barrier on the Env protein. Because Env is heavily glycosylated compared to host glycoproteins, the glycans have be- come targets for the antibody response. Therefore, considerable efforts have been made in developing and validating biophysical methods to elucidate the complex structure of the Env-spike glycoprotein, with its combination of glycan and pr...
Vaccine strategies for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its e...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
The HIV-1 envelope (Env) glycoprotein is the sole HIV-1 surface protein recognized by the humoral an...
Glycans are repeating carbohydrate structures added as post-translational modifications (PTMs) to pr...
SummaryThe HIV envelope glycoprotein (Env) is densely covered with self-glycans that should help shi...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected individuals inform vaccine desi...
Summary The HIV-1-envelope (Env) trimer is covered by a glycan shield of ∼90 N-linked oligosaccharid...
In recent years the glycan shield of the HIV-1 envelope spike (Env) has emerged as a potential targe...
The HIV-1-envelope (Env) trimer is covered by a glycan shield of ∼90 N-linked oligosaccharides, whic...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune response and a cr...
Vaccine strategies for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its e...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
The HIV-1 envelope (Env) glycoprotein is the sole HIV-1 surface protein recognized by the humoral an...
Glycans are repeating carbohydrate structures added as post-translational modifications (PTMs) to pr...
SummaryThe HIV envelope glycoprotein (Env) is densely covered with self-glycans that should help shi...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The high dens...
Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected individuals inform vaccine desi...
Summary The HIV-1-envelope (Env) trimer is covered by a glycan shield of ∼90 N-linked oligosaccharid...
In recent years the glycan shield of the HIV-1 envelope spike (Env) has emerged as a potential targe...
The HIV-1-envelope (Env) trimer is covered by a glycan shield of ∼90 N-linked oligosaccharides, whic...
The HIV-1 envelope glycoprotein trimer (Env) is covered by an extensive array of glycans that shield...
The HIV-1 envelope (Env) glycoprotein is the primary target of the humoral immune response and a cr...
Vaccine strategies for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its e...
SummaryA highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. The hi...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...